Wall Street brokerages expect Illumina, Inc. (NASDAQ:ILMN) to post $860.57 million in sales for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Illumina’s earnings. The highest sales estimate is $870.00 million and the lowest is $855.90 million. Illumina posted sales of $778.00 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 10.6%. The business is scheduled to issue its next quarterly earnings report on Tuesday, January 29th.
On average, analysts expect that Illumina will report full-year sales of $3.33 billion for the current year, with estimates ranging from $3.32 billion to $3.35 billion. For the next year, analysts expect that the business will report sales of $3.79 billion, with estimates ranging from $3.70 billion to $3.97 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Illumina.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 23rd. The life sciences company reported $1.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.26 by $0.26. The company had revenue of $853.00 million for the quarter, compared to the consensus estimate of $825.65 million. Illumina had a return on equity of 27.10% and a net margin of 21.09%. Illumina’s quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.11 EPS.
Several brokerages have commented on ILMN. Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $350.00 price objective on shares of Illumina in a research report on Tuesday, July 31st. Canaccord Genuity reaffirmed a “buy” rating and issued a $340.00 price objective (up previously from $330.00) on shares of Illumina in a research report on Friday, July 27th. Barclays upped their price objective on Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research report on Wednesday, October 24th. Finally, Citigroup upped their price objective on Illumina from $330.00 to $345.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Illumina presently has an average rating of “Buy” and an average target price of $330.94.
Shares of Illumina stock opened at $329.25 on Friday. The firm has a market capitalization of $47.44 billion, a price-to-earnings ratio of 82.31, a price-to-earnings-growth ratio of 2.40 and a beta of 1.07. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. Illumina has a 52 week low of $203.83 and a 52 week high of $372.61.
In other news, Director Robert S. Epstein sold 1,346 shares of the stock in a transaction on Friday, September 7th. The stock was sold at an average price of $345.14, for a total transaction of $464,558.44. Following the transaction, the director now owns 7,139 shares of the company’s stock, valued at approximately $2,463,954.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Marc Stapley sold 1,000 shares of the stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $336.68, for a total value of $336,680.00. Following the transaction, the executive vice president now directly owns 7,757 shares in the company, valued at approximately $2,611,626.76. The disclosure for this sale can be found here. Insiders have sold a total of 53,464 shares of company stock worth $17,883,331 in the last three months. Corporate insiders own 0.54% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of ILMN. Canada Pension Plan Investment Board lifted its stake in shares of Illumina by 272.2% during the 3rd quarter. Canada Pension Plan Investment Board now owns 1,023,452 shares of the life sciences company’s stock worth $375,668,000 after purchasing an additional 748,500 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its stake in shares of Illumina by 2.8% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 88,666 shares of the life sciences company’s stock worth $31,518,000 after purchasing an additional 2,379 shares during the last quarter. Ontario Teachers Pension Plan Board purchased a new stake in shares of Illumina during the 3rd quarter worth $558,000. CIBC World Markets Inc. lifted its stake in shares of Illumina by 55.4% during the 3rd quarter. CIBC World Markets Inc. now owns 21,043 shares of the life sciences company’s stock worth $7,724,000 after purchasing an additional 7,506 shares during the last quarter. Finally, BSW Wealth Partners purchased a new stake in shares of Illumina during the 3rd quarter worth $247,000. 89.90% of the stock is currently owned by institutional investors and hedge funds.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Featured Story: What does EPS mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.